Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The horrific health crisis in Gaza - the World Medical Association and the entire medical community must unequivocally support healthcare professionals and advocate for the end of atrocities perpetrated by the Israeli government.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same author

Resisting Xylella fastidiosa: xylem anatomical changes in the susceptible olive cultivar Cellina di Nardò after long-term infection.

Plant biology (Stuttgart, Germany)·2026
Same author

Bruton's Tyrosine Kinase: A Potential Novel Target for Neurological Disorders.

Physiological research·2025
Same author

Transcriptomic profiling reveals differential cellular response to copper oxide nanoparticles and polystyrene nanoplastics in perfused human placenta.

Environment international·2023
Same author

An ancestral molecular response to nanomaterial particulates.

Nature nanotechnology·2023
Same author

Erratum to "Effect of using mycotoxin-detoxifying agents in dairy cattle feed on natural whey starter biodiversity" (J. Dairy Sci. 105:6513-6526).

Journal of dairy science·2022

相关实验视频

Updated: Jul 7, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

与当代未经治疗的患者相比,治疗齐多夫丁的艾滋病患者的存活率. 意大利Zidovudine评估小组

S Vella1, M Giuliano, P Pezzotti

  • 1Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

JAMA
|March 4, 1992
PubMed
概括

齐杜丁 (AZT) 在获得性免疫缺陷综合征 (AIDS) 患者中显著改善了生存率. 这项观察性研究显示,与未接受治疗的人相比,那些接受AZT治疗的人的中位生存时间更长,两年生存率更高.

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

相关实验视频

Last Updated: Jul 7, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

科学领域:

  • 传染性疾病 传染性疾病
  • 临床医学 临床医学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 在获得性免疫缺陷综合征 (艾滋病) 中对齐多夫丁 (AZT) 的受控试验被提前停止.
  • 以前的生存率比较依赖于历史对照,限制了可靠的评估.
  • 在艾滋病患者中AZT的长期有效性需要进一步评估.

研究的目的:

  • 在被诊断为获得性免疫缺陷综合征 (艾滋病) 的患者中评估齐多丁 (AZT) 的长期疗效.
  • 为了比较AZT治疗患者和未接受治疗的患者之间的生存结果.

主要方法:

  • 在23个意大利艾滋病治疗中心进行了一项非随机的,当代的观察性研究.
  • 该研究包括159名接受AZT治疗的患者和112名未接受治疗的艾滋病患者,主要是通过静脉注射药物使用感染的.
  • 用Kaplan-Meier方法进行生存分析,并使用Cox比例危险回归来确定生存的预测因素.

主要成果:

  • 两组患者在CD4/CD8比率,年龄,性别,临床状况和艾滋病毒感染源方面都相似.
  • 24个月后,AZT治疗组的生存率为45.9%,而未接受治疗组的生存率为20.5%.
  • 治疗患者的中位生存时间为21.2个月,未治疗患者的中位生存时间为9.6个月.

结论:

  • 尽管有潜在的偏差,例如不完美的匹配和治疗患者的更好的整体护理,但观察到的生存差异很可能归因于齐多丁治疗.
  • 这些发现表明,齐多丁对艾滋病患者提供了显著的生存益处.
  • 进一步的研究可能是有必要的,以证实这些长期有效性发现.